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Abstract
Tumor-associated macrophages (TAM) are exposed to multiple
microenvironmental cues in tumors, which collaborate to endow these cells
with protumoral activities. Hypoxia, caused by an imbalance in oxygen supply
and demand because of a poorly organized vasculature, is often a prominent
feature in solid tumors. However, to what extent tumor hypoxia regulates the
TAM phenotype in vivo is unknown. Here, we show that the myeloid infiltrate
in mouse lung carcinoma tumors encompasses two morphologically distinct
CD11b(hi)F4/80(hi)Ly6C(lo) TAM subsets, designated as MHC-II(lo) and MHC-
II(hi) TAM, both of which were derived from tumor-infiltrating Ly6C(hi) monocytes.
MHC-II(lo) TAM express higher levels of prototypical M2 markers and reside
in more hypoxic regions. Consequently, MHC-II(lo) TAM contain higher mRNA
levels for hypoxia-regulated genes than their MHC-II(hi) counterparts. To assess
the in vivo role of hypoxia on these TAM features, cancer cells were inoculated
in prolyl hydroxylase ...
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Abstract
Tumor-associated macrophages (TAM) are exposed to multiple microenvironmental cues in tumors, which
collaborate to endow these cells with protumoral activities. Hypoxia, caused by an imbalance in oxygen supply
and demand because of a poorly organized vasculature, is often a prominent feature in solid tumors. However, to
what extent tumor hypoxia regulates the TAM phenotype in vivo is unknown. Here, we show that the myeloid
inﬁltrate in mouse lung carcinoma tumors encompasses two morphologically distinct CD11bhiF4/80hiLy6Clo
TAM subsets, designated as MHC-IIlo and MHC-IIhi TAM, both of which were derived from tumor-inﬁltrating
Ly6Chi monocytes. MHC-IIlo TAM express higher levels of prototypical M2 markers and reside in more hypoxic
regions. Consequently, MHC-IIlo TAM contain higher mRNA levels for hypoxia-regulated genes than their MHC-
IIhi counterparts. To assess the in vivo role of hypoxia on these TAM features, cancer cells were inoculated in prolyl
hydroxylase domain 2 (PHD2)-haplodeﬁcient mice, resulting in better-oxygenated tumors. Interestingly,
reduced tumor hypoxia did not alter the relative abundance of TAM subsets nor their M2 marker expression,
but speciﬁcally lowered hypoxia-sensitive gene expression and angiogenic activity in the MHC-IIlo TAM subset.
The same observation in PHD2þ/þ ! PHD2þ/ bone marrow chimeras also suggests organization of a better-
oxygenized microenvironment. Together, our results show that hypoxia is not a major driver of TAM
subset differentiation, but rather speciﬁcally ﬁne-tunes the phenotype of M2-like MHC-IIlo TAM. Cancer Res;
74(1); 24–30. 2013 AACR.
Introduction
Tumors are often highly inﬁltrated with inﬂammatory cells,
such as tumor-associated macrophages (TAM). TAM are char-
acterized by plasticity and versatility and may contribute to
tumor progression via several mechanisms, including induc-
tion of angiogenesis, remodeling of the extracellular matrix,
stimulation of cancer cell proliferation andmetastasis, and the
inhibition of adaptive immunity (1, 2).
These different functions are exhibited by distinct TAM
subpopulations, residing in distinct tumormicroenvironments
(3, 4). In this context, it has been observed in several tumor
models that macrophages can inﬁltrate both oxygenized peri-
vascular regions as well as hypoxic tumor areas (4–7). Impor-
tantly, strong tumor hypoxia and a high density of hypoxic
TAM have been shown to correlate with a decreased survival
rate (8). Although hypoxia can inﬂuence monocyte migration
and macrophage proliferation and polarization (9–12), the
precise role of tumor hypoxia in intratumoral monocyte dif-
ferentiation and in shaping the molecular and functional TAM
phenotype remains largely unexplored.
In this study, we used prolyl hydroxylase domain 2 (PHD2)-
haplodeﬁcient mice to evaluate the impact of tumor hypoxia
on M2-like MHC-IIlo and M1-like MHC-IIhi TAM subpopula-
tions, which both differentiate from Ly6Chi monocytes but
reside in strongly hypoxic and less hypoxic regions, respec-
tively. The oxygen-sensing PHD2 protein targets hypoxia-
inducible transcription factors (HIF) for degradation. Hence,
its haplodeﬁciency creates a "genetic" type of hypoxia, resulting
in tumor vessel normalization and tumor oxygenation (13).
Using PHD2þ/ tumors, we demonstrated that hypoxia does
not govern TAM subset differentiation and polarization, but
regulates hypoxia-sensitive genes and angiogenic activity
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speciﬁcally in MHC-IIlo TAM. Moreover, the diminished hyp-
oxic signature ofMHC-IIlo TAM is recapitulated in PHD2þ/þ!
PHD2þ/ bone marrow chimeras, illustrating that a better-
oxygenized microenvironment drives this phenomenon.
Materials and Methods
More detailed materials and methods can be found in the
supplementary material.
Mice, cell line, and tumor models
Female C57BL/6 mice were from Janvier. PHD2þ/ and
Cx3cr1gfp/þ mice were provided by Peter Carmeliet (VIB-
KULeuven) and Frank Tacke (Aachen University), respectively.
Procedures followed the guidelines of the Belgian Council for
Laboratory Animal Science.
Mice were injected subcutaneously with 3 106, or ortho-
topically with 5  105, 3LL-R Lewis lung carcinoma cells.
Tumor preparation, ﬂow cytometry, and cell sorting
Tumor single-cell suspensions from subcutaneous and
orthotopic 3LL-R tumors and sorted TAM were prepared as
described (4). Commercial antibodies for cell surface stainings
are listed in Supplementary Table S1. To prevent aspeciﬁc
binding, TAMs were preincubated with rat anti-mouse CD16/
CD32 (clone 2.4G2; BD Biosciences).
To purify TAM or tumor-associated dendritic cells (TADC),
cells were sorted using a BD FACSAria II (BD Biosciences)
from 6 to 8 pooled tumors. To purify splenic conventional
dendritic cells (DC), spleens were ﬂushed with 200 U/mL
collagenase III (Worthington) and squashed. Subsequently,
CD11cþ cells were enriched via MACS, using anti-CD11c
microbeads (Miltenyi Biotec), after which CD11cþMHC-
IIhiB220Ly6C DCs were sorted using a BD FACSAria II.
Normalized delta-median ﬂuorescence intensity (DMFI) was
calculated as: [(MFI iNOS staining) (MFI isotype staining)]/
(MFI iNOS staining). FACS data were acquired using a BD
FACSCanto II (BD Biosciences).
RNA extraction, cDNA preparation, and quantitative
real-time PCR
These experiments were performed as described (4). RNA
was extracted using TRIzol (Invitrogen) and was reverse-
transcribed with oligo(dT) and SuperScript II RT (Invitrogen).
Quantitative real-time PCR (qRT-PCR) was performed in an
iCycler, with iQ SYBR Green Supermix (Bio-Rad). Primer
sequences are listed in Supplementary Table S2. PCR cycles
consisted of 10 94C, 4500 55C, 10 72C. Gene expression was
normalized using ribosomal protein S12 (Mrps12) as a house-
keeping gene.
Measurement of arginase activity, NO, and
interleukin-10 production
The arginase activity in the lysate of 5  105 sorted TAM or
TADCwasmeasured as described (4) andNO2
was quantiﬁed
by a Griess reaction (4). Interleukin (IL)-10 concentrations
were measured by Bio-Plex (Bio-Rad), according to the sup-
plier's protocols.
Statistics
Signiﬁcance was determined by the Student t test, using
GraphPad Prism 4.0 software.
Results
Lung carcinomas are highly inﬁltrated with a
heterogeneous myeloid cell compartment
To study the impact of hypoxia on tumor-associated macro-
phages, we investigated established subcutaneous 3LL-R
tumors with an average tumor volume of 869 75 mm3. These
tumors possessed hypoxic areas, as demonstrated by pimoni-
dazole staining (Fig. 1A), and are highly inﬁltrated by CD11bhi
myeloid cells (51.7  10.8% of the tumor single-cell
suspension; Fig. 1B). The myeloid inﬁltrate encompassed
Ly6Ghi neutrophils (12.0  3.5% within CD11bhi cells) and
different mononuclear phagocyte subsets in various stages of
differentiation: Ly6ChiCCR2hiCX3CR1
intMHC-IIneg monocytes
(gate 1; Fig. 1B), Ly6CintCCR2loCX3CR1
intMHC-IIlo immature
macrophages (gate 2), Ly6Chi/intCCR2loCX3CR1
intMHC-IIhi
immature macrophages (gate 3), Ly6CloCCR2negCX3CR1-
loMHC-IIlo tumor-associated macrophages (MHC-IIlo TAM,
gate 4), Ly6CloCCR2loCX3CR1
hiMHC-IIhi tumor-associated
macrophages (MHC-IIhi TAM, gate 5), and Ly6Clo
CCR2negCX3CR1
hiMHC-IIhi tumor-associated DC (TADC, gate
6). All macrophage subsets showed a high expression of F4/80
and a typical macrophage scatter proﬁle, whereas the TADC
expressed higher levels of MHC-II, CD11c, costimulatory, and
antigen-presenting molecules, but lower F4/80, CD64, and
MerTK (Fig. 1C and Supplementary Fig. S1A), in combination
with a characteristic DC morphology (Fig. 1B). In a mixed
leukocyte reaction, both TAM subsets were poor stimulators of
naive CD4þ and CD8þ T cells compared with TADC, which are
equally potent antigen-presenting cells as splenic conventional
DC (Fig. Supplementary S1B and S1C). Moreover, at higher
cell densities both TAM subsets suppress T-cell proliferation
(Supplementary Fig. S1B and S1C).
MHC-IIlo and MHC-IIhi TAM were morphologically distinct
(Fig. 1B), suggestive of a different activation state. In agreement
with this notion, enhanced protein expression of prototypic
M2-associated markers such as MMR, IL-4Ra, SR-A, stabilin-1,
arginase-1, and IL-10 and reduced iNOS activity illustrate the
moreM2-like nature ofMHC-IIlo TAMas comparedwithMHC-
IIhi TAM (Fig. 1C and D).
To extrapolate these ﬁndings to orthotopically grown
tumors, 3LL-R was injected intrathoracically. Orthotopic
lung tumors contained similar myeloid cell subsets, except
for TADC (Supplementary Fig. S2A), with similar M1-like
versus M2-like proﬁles for the MHC-IIhi and MHC-IIlo TAM,
respectively (Supplementary Fig. S2B). Notably, the propor-
tion of distinct lung monocyte and macrophage populations
was largely comparable between peritumoral normal lung
tissue and naive lungs (Supplementary Fig. S2C).
MHC-IIlo and MHC-IIhi TAM are derived from the same
monocyte precursor but reside in differentially
oxygenized tumor regions
TAM subsets could be different because they are derived
from distinct monocyte precursors or because they are subject
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to distinct microenvironments. Ly6CloCX3CR1
hi monocytes are
nearly undetectable at the tumor site (data not shown). More-
over, selective labeling of Ly6Chi or Ly6Clo monocytes in the
circulation and subsequent tracing of labeled monocyte prog-
eny in the tumor illustrated that exclusively Ly6Chi monocytes
give rise to both TAM populations (Fig. 2A). Furthermore,
continuous administration of BrdU to the drinking water
demonstrated that tumor-inﬁltrating Ly6Chi monocytes and
both immature macrophage populations, all of which do not
proliferate as illustrated by cell-cycle analysis (data not shown),
rapidly become >90% BrdUþ, suggesting these cells are differ-
entiation intermediates with a fast turnover rate (Fig. 2B).
Notably, immature macrophages show a lag phase of BrdU
incorporation relative to the Ly6Chi monocytes (at 24 hours:
72,5% BrdUþLy6Cþmonocytes, 38% BrdUþMHC-IIhi immature
TAM, 11% BrdUþMHC-IIlo immature TAM) and mature MHC-
IIhi and MHC-IIlo TAM show a lag phase relative to immature
macrophages (at 48 hours: 76% BrdUþ immature macrophages,
14% BrdUþMHC-IIhi TAM, 9% BrdUþMHC-IIlo TAM), propos-
ing a Ly6Chi monocyte ! MHC-IIlo and MHC-IIhi immature
TAM!MHC-IIlo andMHC-IIhi TAMdifferentiation scheme. By
day 7, 79% of MHC-IIhi TAM are BrdUþ compared with only
67% MHC-IIlo TAM, suggesting a somewhat faster turnover
rate of the former population.
Because both TAM populations were derived from the same
precursor, we next assessed their intratumoral localization. The
hypoxia tracer pimonidazole was injected in tumor-bearing
mice and 2 hours later intracellular hypoxyprobe staining was
performed on tumor single-cell suspensions. Immature MHC-
IIlo macrophages and especially MHC-IIlo TAM stained much
brighter compared with their MHC-IIhi counterparts (Fig. 2C).
In line with these ﬁndings, F4/80þMHC-IIhi cells were located
outside of hypoxyprobe (HP-1)þ tumor regions in immunohis-
tochemistry (Fig. 2D) and were not contained within the HP-1hi
cell fraction in ﬂow cytometry (Supplementary Fig. S3A). Con-
versely, the hypoxic regions in immunohistochemistry and
the HP-1hi fraction in ﬂow cytometry contained F4/80þ cells
that were mainly MHC-IIneg/lo. Moreover, by gating on the
CD11bþLy6GLy6C (encompassing only mature TAM and
TADC subsets) HP–1high versus HP-1low cells, a higher expres-
sion of MMR, IL-4Ra, and SR-A could be detected on the HP-
1high fraction, corroborating the presence of the more M2-like
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Figure 1. 3LL-R tumors are hypoxic and inﬁltrated by distinct mononuclear phagocyte subsets. A, frozen tumor sections from HP-1–injected mice were
stained for HP-1 adducts and DAPI. B, single-cell suspensions of 13-day-old 3LL-R tumors were stained for the indicated markers. Percentages
represent the mean  SD within the CD11bþLy6G population. Forward scatter versus side scatter plots and cytospins (scale bar, 10 mm) or histogram
overlays (C) are shown. Shaded histogram, expression of the indicated marker; black line, isotype control. D, arginase enzymatic activity was
measured in lysates of 5  105 sorted TAM or TADC. Spontaneous IL-10 and NO production was measured upon 48 hours in vitro culture (3  105 TAM
or TADC per 200 mL medium). Graphs show mean  SEM. , P < 0.05; , P < 0.01. All experiments, n  6.
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MHC-IIlo TAM in this fraction. In conclusion, MHC-IIlo TAM
rather associate with hypoxic regions, whereas MHC-IIhi TAM
reside in less hypoxic areas.
Hypoxia does not deﬁne TAM differentiation and
polarization, but speciﬁcally ﬁne-tunes the molecular
and functional proﬁle of the MHC–IIlo TAM subset
To address whether hypoxia is the driving force behind TAM
subset differentiation, 3LL-R tumors were inoculated in
PHD2þ/ mice. PHD2-haplodeﬁciency was shown before to
foster vessel maturation and enhanced tumor oxygenation in
several mouse tumor models without affecting primary tumor
growth (13). Accordingly, overall oxygen pressure was signif-
icantly increased and the hypoxic HP-1þ area signiﬁcantly
reduced in PHD2þ/ 3LL-R tumors (Fig. 3A and B). Tumor
perfusion (Supplementary Fig. S4B–S4D) and vessel coverage
(Supplementary Fig. S4E–S4G) were also signiﬁcantly higher in
PHD2þ/ tumors, whereas vessel density remained unchanged
(Supplementary Fig. S4A), indicating that these vessels were
more mature, tight, and stable. However, nearly no differences
were observed at the level of myeloid cell inﬁltration,
the relative abundance of MHC-IIlo and MHC-IIhi TAM, or the
expression of prototypical M2 markers in these cells (Fig. 3C
and D). Hence, hypoxia is not the main driver of TAM subset
differentiation and polarization inside tumors.
We then assessed whether hypoxia contributes to a ﬁne-
tuning of the TAM phenotype. Corroborating their association
with hypoxic regions, many of the hypoxia-dependent genes
[Vegfa, Angpt2, Flt1 (VEGFR1), Kdr (VEGFR2), Egf, Slc2a1
(Glut1), Slc2a3 (Glut3), Ldha, Plau (uPA), Igf1, Serpine1 (PAI-
1), Nos2 (iNOS), and Cxcl1 (KC)] were signiﬁcantly upregulated
in MHC-IIlo TAM compared with MHC-IIhi TAM in control
tumors (Fig. 4A). Interestingly, genes regulating angiogenesis,
metabolism, or cancer cell invasiveness such as Vegfa, Slc2a1,
Slc2a3, Serpine1, Plau,Nos2, andCxcl1were signiﬁcantly down-
regulated in MHC-IIlo TAM from PHD2þ/ tumors compared
with MHC-IIlo TAM of control tumors. In contrast, the expres-
sion level of these hypoxia-regulated genes was less altered in
MHC–IIhi TAM of both genotypes. Hence, hypoxia regulates
the expression of a subset of genesmainly in theMHC-IIlo TAM
population. For VEGF-A, GLUT-3, GLUT-1, and iNOS, these
ﬁndings could be recapitulated at the protein level (Supple-
mentary Fig. S5A and S5B). In agreement, the in vivo angiogenic
activity ofMHC-IIlo TAM from PHD2þ/ tumors is signiﬁcantly
reduced as compared with theirWT counterparts whereas this
is not the case for MHC-IIhi TAM (Fig. 4B).
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Figure 2. TAMsubsets are derived from the samemonocyteprecursor but reside indifferentially oxygenized tumor regions.A, thepercentageofﬂuorescent latexþ
cells inﬁltrating 6-day-old 3LL-R tumors from untreatedmice (No Lx) or frommice inwhich the Ly6Clo (þLx) or Ly6Chi (þCLLþLx) bloodmonocytes were labeled
are shown. In addition, Ly6C versus MHC-II plots of the gated total CD11bþLy6G population or the latexþCD11bþLy6G population within 3LL-R tumors
(Ly6Chi blood monocyte labeled) are shown. B, kinetics of BrdU incorporation in the distinct TAM subsets. Ten days 3LL-R tumor-bearing mice were left
untreated (0 hour) or continuously given BrdU in the drinking water for the indicated time periods, after which tumors were collected. BrdU incorporation was
measured using intracellular ﬂow cytometry. The graph shows the percentage of BrdUþ cells within the gated subpopulation after different time points of
BrdU administration. C, 3LL-R tumor-bearing mice were left untreated (control) or were injected with pimonidazole (HP-1). Tumors were then collected and
the presence of HP-1 adducts on gated TAM subsets was assessed using intracellular ﬂow cytometry.DMFI¼MFI HP1MFI control. D, frozen tumor sections
from HP-1 injected mice were triple stained for F4/80, MHC-II, and HP-1 adducts. Nuclei were stained using DAPI. All experiments, n  6.
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A potential caveat for the interpretation of the results in
PHD2þ/ mice is the fact that also the macrophages in these
mice are PHD2-haplodeﬁcient, and hence experience a "genetic
type" of hypoxia with a potential skewing of their activation
state (14). Therefore, we inoculated 3LL-R in PHD2þ/þ !
PHD2þ/ bone marrow chimeric mice (microenvironmental
haplodeﬁciency) versus PHD2þ/þ! PHD2þ/þ controls. Tumor
hypoxic areas were smaller in the former (Fig. 4C), illustrating
that PHD2-haplodeﬁciency in nonhematopoietic cells is sufﬁ-
cient to increase oxygenation. In line with the data in PHD2þ/
mice, many hypoxia-regulated genes were signiﬁcantly down-
regulated in MHC-IIlo, but not MHC-IIhi, TAM from tumors
grown in PHD2þ/þ ! PHD2þ/ mice (Fig. 4D). These data
corroborate the conclusion that environmental hypoxiamainly
affects the MHC-IIlo TAM phenotype.
Discussion
TAM reside in a complexmicroenvironment, so theirmolec-
ular and functional proﬁle is under the inﬂuence of multiple
factors. In vivo evidence exists for the role of immune cell- and
cancer cell-derived factors (e.g., cytokines such as IL–4 and IL-
10, immunoglobulins, prostaglandin E2, exosomes) in shaping
the protumoral functions of TAM during tumor progression
(15,16). However, the impact of tumor hypoxia (0.1–3% O2) is
less clear in this respect, despite the known association of
macrophages with hypoxic regions (4–7).
Indeed, our data demonstrate the existence of at least 2main
TAM subsets, discriminated mainly by the differential MHC–II
expression level, in subcutaneous and orthotopic lung carci-
nomas. Hereby the MHC-IIlo subpopulation resides in more
hypoxic regions as illustrated by intracellular FACS staining
and immunohistochemistry upon pimonidazole treatment
of the tumors. Earlier ﬁndings also pointed to the coexistence
of TAM within hypoxic and less hypoxic regions in models of
mousemammary (4, 5) andhumanprostate carcinoma (6). The
molecular mechanisms responsible for the guidance of TAM
toward hypoxic areas are not entirely clear, but it has been
shown that the angiopoietin-2/Tie2 interaction regulates the
vascular proximity of MMRþTie2þ macrophages (17). Impor-
tantly, both TAM subsets derive from a common Ly6Chi
monocyte precursor that continuously seeds the tumor, sug-
gesting that distinct intratumoral cues drive the differentiating
monocytes either to an MHC-IIlo or MHC-IIhi phenotype. One
of the outstanding questions was whether hypoxia itself is the
driving force behind this dichotomous monocyte differentia-
tion. In addition, hypoxic MHC-IIlo TAM express higher levels
of prototype M2 markers such as MMR, IL-4Ra, and arginase,
and it was unclear whether this activation state is regulated by
oxygen deprivation.
We used PHD2-haplodeﬁcient mice as a tool to directly alter
oxygen availability in the tumor. Mazzone and colleagues (13)
had demonstrated that the tumor vessels in these mice are
more mature, increasing oxygen transport to the tumor, and
that an endothelial cell-restricted PHD2-haplodeﬁciency is
sufﬁcient to drive this phenomenon. In agreement with these
ﬁndings, oxygen pressure increases and the hypoxic area
diminishes in 3LL-R tumors grown in PHD2þ/ mice, as well
as in PHD2þ/þ ! PHD2þ/ chimeras. It is important to note
Figure 3. Characterization of 3LL-R tumors in PHD2þ/mice. 3LL-R tumors were grown for 12 days in PHD2þ/þ and PHD2þ/mice, after which intratumoral
pO2 (A) wasmeasured via EPRoxymetry (n¼ 5) andmorphometric quantiﬁcation (B) of HP-1 staining on tumor slideswas performed (n¼5). C, the percentage
of CD11bþ cells (within the total tumor single-cell suspension) and the percentage of mononuclear phagocyte subsets (within the gated CD11bþ population)
were determined (n¼ 6). D, surface marker expression for the M2markers MMR and IL-4Ra on TAM of PHD2þ/þ and PHD2þ/ tumors was assessed by ﬂow
cytometry. Shaded histogram, expression of the indicatedmarker; black line, isotype control. Arginase enzymatic activity wasmeasured in lysates of 5 105
sorted TAM from a pool of 6 tumor-bearing mice.
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that this approach more directly assesses the overall impact of
hypoxia on tumor macrophages, in contrast to studies where
macrophages were engineered to lack only HIF-1a or HIF-2a
(18,19). Moreover, HIFs also act on gene transcription in a
hypoxia-independent fashion, whereby HIF-1a is induced
by Th1 cytokines in pro-inﬂammatory M1 macrophages and
Figure 4. Inﬂuence of environmental hypoxia on the gene expression proﬁle and angiogenic activity of TAMsubsets. A, expression of hypoxia-regulated genes
in sorted MHC-IIlo and MHC-IIhi TAM from 13-day-old 3LL-R tumors grown in PHD2þ/ or PHD2þ/þmice was assessed using qRT-PCR. The expression of
each gene was normalized based on the S12 housekeeping gene and is shown as the fold induction compared with the expression in sorted peritoneal
macrophages. B, sorted MHC-IIlo and MHC-IIhi TAM from 12-day-old 3LL-R tumors grown in PHD2þ/ and PHD2þ/þ mice were grafted on the developing
chorioallantoic membrane from fertilized chicken eggs. BSA and rhVEGF were used as negative and positive controls, respectively. The number of vessels
growing toward the implants was quantiﬁed and this region was photographed. Values are the mean number of implant-directed vessels  SEM. C, tumor
sections from 3LL-R tumors grown in PHD2þ/þ! PHD2þ/ and control PHD2þ/þ ! PHD2þ/þ bone marrow chimeras were frozen upon HP-1 injection and
were stained for HP-1 adducts andDAPI. Mean%HP-1 areaSEMare given. D, gene expression of sortedMHC-IIlo andMHC-IIhi TAMgrown inPHD2þ/þ!
PHD2þ/ bone marrow chimeras. Expression levels were ﬁrst normalized based on the S12 gene and calculated as the fold induction compared with the
expression in sorted peritoneal macrophages. Bars represent the up- or downregulation of the expression of the indicated genes, compared with the
corresponding TAM subset in control bone marrow chimeras. All experiments, n  3. , P < 0.05; , P < 0.01; , P < 0.001.
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HIF-2a by Th2 cytokines inM2macrophages (20). Our ﬁndings
in PHD2-haplodeﬁcient mice demonstrate that the tumor oxy-
genation state does not signiﬁcantly alter the attraction of
monocytes to the tumor nor the efﬁciency of monocyte differ-
entiation into M2-like MHC-IIlo or M1-like MHC-IIhi TAM.
Reduced hypoxia also does not seem to affect the expression
of suchM2-markers asMMR, IL-4Ra, and arginase inMHC-IIlo
TAM, but rather downregulates their expression of typical
hypoxia-responsive genes involved in glycolysis (Slc2a1, Slc2a3,
Ldha), angiogenesis (Vegfa, Angpt1, Angpt2, Kdr, Nos2, Cxcl1),
and metastasis (Egf, uPA, uPAR, Igf1, Serpine1). These results
were phenocopied in PHD2þ/þ! PHD2þ/ chimeras, illustrat-
ing that the PHD2-haplodeﬁciency in macrophages does not
majorly account for the observed changes in gene expression.
Together, our data suggest a model whereby tumor-inﬁl-
trating Ly6Chi monocytes either become MHC-IIlo M2-like
TAM or MHC-IIhi M1-like TAM under the inﬂuence of micro-
environmental stimuli other than hypoxia. Once formed,MHC-
IIlo TAM are preferentially attracted to hypoxic regions where
they upregulate hypoxia-regulated genes and their angiogenic
capacity. By contrast, MHC-IIhi TAM remain largely unaffected
by hypoxia.
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